Albany, NY -- (SBWIRE) -- 07/19/2019 -- Primary Hyperoxaluria Market Insights, Epidemiology and Market Forecast-2028
1. Primary Hyperoxaluria total diagnosed prevalent population in 7 major markets were observed to be 3,878 in 2017.
2. Primary Hyperoxaluria diagnosed cases were 3,000 in 2017 in the United States.
3. The lowest Primary Hyperoxaluria diagnosed prevalent population in Japan were73 cases.

(Albany, US) DelveInsight launched a new report on Primary Hyperoxaluria Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Primary Hyperoxaluria Market report covers a descriptive overview and comprehensive insight of the Primary Hyperoxaluria epidemiology and Primary Hyperoxaluria market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Primary Hyperoxaluria market report provides insights on the current and emerging therapies.
3. Primary Hyperoxaluria Market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Primary Hyperoxaluria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Primary Hyperoxaluria market.

Request for sample pages

"Based on age-group, the highest number of Primary Hyperoxaluria patients were observed for 0-4 years in the United States, followed by those in the age group 5-9 years. In contrast, the least patient population was witnessed by those aged 40-44 years."

Primary Hyperoxaluria market size in the seven major markets was observed to be USD 344.79 million in 2017, which is further expected to increase during the study period (2017-2028). Expected Launch of potential therapies may increase Primary Hyperoxaluria market size in the coming years, assisted by an increase in Primary Hyperoxaluria diagnosed prevalent population.
At present, there are no approved therapies for Primary Hyperoxaluria treatment and the current Primary Hyperoxaluria therapeutic market is based on the therapies such as Enzyme reactivation therapy, Gene therapies and Substrate reduction therapy through RNA-interference. Other treatment options include chemical chaperones, supplements intake, hepatocyte transplantation, dialysis whereas the general therapies for nephrolithiasis benefit all individuals. Drugs such as thiazides and potassium citrate or neutral orthophosphates can decrease urinary calcium excretion and inhibit stone formation, respectively.

Primary Hyperoxaluria market dynamics is anticipated to change owing to the expected launch of emerging therapies during the forecasted period of 2019-2028 such as
1. DCR-PHXC
2. ALLN-177
3. Oxabact
4. Lumasiran
And many others

Companies involved are-

1. Alnylam Pharma
2. Dicerna Pharmaceuticals
3. Allena Pharmaceuticals
4. OxThera
And many others

Table of contents

1. Key Insights
2. Primary Hyperoxaluria Market Overview at a Glance
3. Primary Hyperoxaluria Disease Background and Overview
4. Primary Hyperoxaluria Epidemiology and Patient Population
5. Primary Hyperoxaluria Total Diagnosed Prevalent Patient Population 7MM
6. Country Wise Primary Hyperoxaluria Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. Spain
6.7. United Kingdom
7. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices
8. Primary Hyperoxaluria Unmet Needs
9. Primary Hyperoxaluria Emerging Drugs
9.1. Key Cross Competition
9.2. Oxabact: OxThera
9.3. Lumasiran: Alnylam Pharmaceuticals
9.4. ALLN-177: Allena Pharmaceuticals
10. Primary Hyperoxaluria 7 Major Market Analysis
11. The United States Market Outlook
12. EU-5 Countries: Market Outlook
12.1. Germany
12.2. France
12.3. Italy
12.4. Spain
12.5. United Kingdom
12.6. Japan: Market Outlook
13. Market Drivers
14. Market Barriers
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight